Patents by Inventor Wei-Ying Kuo
Wei-Ying Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10752673Abstract: Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads.Type: GrantFiled: June 12, 2017Date of Patent: August 25, 2020Assignee: ACADEMIA SINICAInventors: An-Suei Yang, Hong-Sen Chen, Chung-Ming Yu, Shin-Chen Hou, Wei-Ying Kuo, Yi-Kai Chiu, Yueh-Liang Tsou, Hung-Ju Hsu, Hwei-Jiung Wang, Shih-Hsien Chuang, Chao-Pin Lee
-
Patent number: 10562976Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.Type: GrantFiled: October 22, 2018Date of Patent: February 18, 2020Assignee: Academia SinicaInventors: An-Suei Yang, Wei-Ying Kuo, Hung-Ju Hsu, Hong-Sen Chen, Yu-Chi Chou, Yueh-Liang Tsou, Hung-Pin Peng, Jhih-Wei Jian, Chung-Ming Yu, Yi-Kai Chiu, Ing-Chein Chen, Chao-Ping Tung, Michael Hsiao, Hwei-Jiung Wang
-
Patent number: 10415033Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.Type: GrantFiled: November 28, 2018Date of Patent: September 17, 2019Assignee: Academia SinicaInventors: An-Suei Yang, Jhih-Wei Jian, Hong-Sen Chen, Yi-Kai Chiu, Hung-Pin Peng, Chao-Ping Tung, Chung-Ming Yu, Wei-Ying Kuo, Hung-Ju Hsu
-
Publication number: 20190085323Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.Type: ApplicationFiled: November 28, 2018Publication date: March 21, 2019Applicant: Academia SinicaInventors: An-Suei Yang, Jhih-Wei Jian, Hong-Sen Chen, Yi-Kai Chiu, Hung-Pin Peng, Chao-Ping Tung, Chung-Ming Yu, Wei-Ying Kuo, Hung-Ju Hsu
-
Publication number: 20190040151Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.Type: ApplicationFiled: October 22, 2018Publication date: February 7, 2019Applicant: Academia SinicaInventors: An-Suei YANG, Wei-Ying KUO, Hung-Ju HSU, Hong-Sen CHEN, Yu-Chi CHOU, Yueh-Liang TSOU, Hung-Pin PENG, Jhih-Wei JIAN, Chung-Ming YU, Yi-Kai CHIU, Ing-Chein CHEN, Chao-Ping TUNG, Michael HSIAO, Hwei-Jiung WANG
-
Publication number: 20170355750Abstract: Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads.Type: ApplicationFiled: June 12, 2017Publication date: December 14, 2017Applicant: Academia SinicaInventors: An-Suei YANG, Hong-Sen CHEN, Chung-Ming YU, Shin-Chen HOU, Wei-Ying KUO, Yi-Kai CHIU, Yueh-Liang TSOU, Hung-Ju HSU, Hwei-Jiung WANG, Shih-Hsien CHUANG, Chao-Pin LEE
-
Patent number: 7507532Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.Type: GrantFiled: March 7, 2005Date of Patent: March 24, 2009Assignee: Medigen Biotechnology CorporationInventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho
-
Publication number: 20080305188Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.Type: ApplicationFiled: April 3, 2003Publication date: December 11, 2008Inventors: Hsun-Lang Chang, Wu-Chang Chuang, Wei-Ying Kuo, Guang-Tzuu Shane, Hung-Sheng Chang
-
Publication number: 20080119567Abstract: The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na+/K+-ATPase to strengthen heart muscle contractions and prevent heart failure.Type: ApplicationFiled: November 20, 2007Publication date: May 22, 2008Inventors: Andy A.T. Fong, Guang-Tzuu Shane, Hsun-Lang Chang, Wei-Ying Kuo
-
Publication number: 20080020386Abstract: A method for determining the human leukocyte antigen (HLA) genotype of a nucleic acid sample, comprises: contacting a nucleic acid sample with at least one nucleic acid primer set and subjecting the mixture to a nucleic acid amplification reaction; determining the size of any amplification products produced in the amplification reaction; and correlating the presence and/or absence of specific amplification products with the presence and/or absence of specific sequence polymorphisms in the nucleic acid sample. At least one of the primer sets is a multi-specific primer set comprising at least one sequence-specific forward primer and at least one sequence-specific reverse primer and being adapted to amplify two or more specific target sequences in the nucleic acid sample. Each of the specific target sequences comprises a sequence polymorphism that is known to be associated with an HLA allele and which may be present in the nucleic acid sample to be genotyped.Type: ApplicationFiled: March 28, 2007Publication date: January 24, 2008Applicant: MEDIGEN BIOTECHNOLOGY CORPORATIONInventors: Chaw Yuan Michael Chen, Yen-Chin Chen, Wei-Ying Kuo, Chiao-Chien Hung
-
Publication number: 20070166404Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.Type: ApplicationFiled: April 3, 2003Publication date: July 19, 2007Inventors: Hsun-Lang Chang, Wu-Chang Chuang, Wei-Ying Kuo, Guang-Teuu Shane, Hung-Sheng Chang
-
Publication number: 20060068411Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.Type: ApplicationFiled: March 7, 2005Publication date: March 30, 2006Applicant: Medigen Biotechnology CorporationInventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho
-
Publication number: 20050153352Abstract: MG20 (CCNDBP1) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MG20 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MG20 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MG20 expression or activity, thereby treating cancer, in vivo.Type: ApplicationFiled: January 7, 2005Publication date: July 14, 2005Inventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li